Sec Form 4 Filing - Israel Biotech Fund I, L.P. @ Ayala Pharmaceuticals, Inc. - 2024-02-07

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Israel Biotech Fund I, L.P. 2. Issuer Name and Ticker or Trading Symbol Ayala Pharmaceuticals, Inc. [ ADXS] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 75 FORT STREET, CLIFTON HOUSE,, PO BOX, 1350 3. Date of Earliest Transaction (MM/DD/YY) 02/07/2024 (Street) GRAND CAYMAN, E9KY1-1108 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock, par value $0.001 per share 02/07/2024( 1 ) M 1,926,221 ( 1 ) A ( 1 ) $ 0.4 ( 1 ) 11,044,282 I See footnote ( 2 ) Common Stock, par value $0.001 per share 02/07/2024( 1 ) M 4,237,687 ( 1 ) A ( 1 ) $ 0.4 ( 1 ) 18,359,495 I See footnote ( 3 ) Common Stock, par value $0.001 per share 02/07/2024( 4 ) M 3,887,438 ( 4 ) A ( 4 ) $ 0.4 ( 4 ) 14,931,720 I See footnote ( 2 ) Common Stock, par value $0.001 per share 02/07/2024( 4 ) M 1,295,813 ( 4 ) A ( 4 ) $ 0.4 ( 4 ) 19,655,308 I See footnote ( 3 ) Common Stock, par value $0.001 per share 02/07/2024( 5 ) M 8,437,500 ( 5 ) A ( 5 ) $ 0.4 ( 5 ) 23,369,220 I See footnote ( 2 ) Common Stock, par value $0.001 per share 02/07/2024( 5 ) F 2,707,581 ( 5 ) D ( 5 ) $ 1.2465 ( 5 ) 20,661,639 I See footnote ( 2 ) Common Stock, par value $0.001 per share 02/07/2024( 5 ) M 8,062,500 ( 5 ) A ( 5 ) $ 0.4 ( 5 ) 27,717,808 I See footnote ( 3 ) Common Stock, par value $0.001 per share 02/07/2024( 5 ) F 2,586,905 ( 5 ) D ( 5 ) $ 1.2465 ( 5 ) 25,130,903 I See footnote ( 3 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Convertible Promissory Note $ 0.4 ( 1 ) 02/07/2024( 1 ) M 1,926,221 ( 1 ) 11/17/2023 11/17/2028 Common Stock 1,926,221 ( 1 ) ( 1 ) 13,661,159 I See footnote ( 2 ) Convertible Promissory Note $ 0.4 ( 1 ) 02/07/2024( 1 ) M 4,237,687 ( 1 ) 11/17/2023 11/17/2028 Common Stock 4,237,687 ( 1 ) ( 1 ) 18,996,000 I See footnote ( 3 ) Convertible Promissory Note $ 0.4 ( 4 ) 02/07/2024( 4 ) M 3,887,438 ( 4 ) 11/17/2023 11/17/2028 Common Stock 3,887,438 ( 4 ) ( 4 ) 11,724,938 I See footnote ( 2 ) Convertible Promissory Note $ 0.4 ( 4 ) 02/07/2024( 4 ) M 1,295,813 ( 4 ) 11/17/2023 11/17/2028 Common Stock 1,295,813 ( 4 ) ( 4 ) 14,758,313 I See footnote ( 3 ) Warrants $ 0.4 ( 1 ) 02/07/2024( 1 ) M 8,437,500 ( 1 ) ( 5 ) 11/17/2023 11/17/2028 Common Stock 8,437,500 ( 1 ) ( 5 ) ( 1 ) ( 5 ) 7,837,500 ( 6 ) I See footnote ( 2 ) Warrants $ 0.4 ( 1 ) 02/07/2024( 1 ) M 8,062,500 ( 1 ) ( 5 ) 11/17/2023 11/17/2028 Common Stock 8,062,500 ( 1 ) ( 5 ) ( 1 ) ( 5 ) 13,462,500 ( 6 ) I See footnote ( 3 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Israel Biotech Fund I, L.P. 75 FORT STREET, CLIFTON HOUSE, PO BOX, 1350 GRAND CAYMAN, E9KY1-1108 X X Israel Biotech Fund II, L.P. 75 FORT STREET, CLIFTON HOUSE, PO BOX, 1350 GRAND CAYMAN, E9KY1-1108 X X Israel Biotech Fund GP Partners, L.P. 75 FORT STREET, CLIFTON HOUSE, PO BOX, 1350 GRAND CAYMAN, E9KY1-1108 X X Israel Biotech Fund GP Partners II, L.P. 75 FORT STREET, CLIFTON HOUSE, PO BOX, 1350 GRAND CAYMAN, E9KY1-1108 X X I.B.F. Management Ltd. 4 OPPENHEIMER ST. REHOVOT, L37670104 X X Signatures /s/ Yuval Cabilly, Managing Partner 02/12/2024 Signature of Reporting Person Date /s/ Yuval Cabilly, Managing Partner 02/12/2024 Signature of Reporting Person Date /s/ Yuval Cabilly, General Partner 02/12/2024 Signature of Reporting Person Date /s/ Yuval Cabilly, General Partner 02/12/2024 Signature of Reporting Person Date /s/ Yuval Cabilly, Chief Executive Officer 02/12/2024 Signature of Reporting Person Date

Explanation of Responses:

( 1 )On 11/17/2023, Issuer issued to Israel Biotech Fund I, L.P. ("IBF 1") and IBF II Israel Biotech Fund II, L.P. ("IBF 2") Senior Convertible Promissory Notes, with a principal amount of $750,000 and $1,650,000, respectively (the "Notes"), and, in connection therewith, warrants to purchase 2,812,500 shares of Common Stock and 6,187,500 shares of Common Stock, respectively, at an exercise price of $0.40 per share, subject to adjustments (the "Warrants"). As more fully described in a Schedule 13D/A filed by the Reporting Persons on 2/12/2024 (the "Schedule 13D/A"), on 2/7/2024 the Notes were converted into 1,926,221 shares of Common Stock and 4,237,687 shares of Common Stock, respectively, which number of shares represents the aggregate principal amount plus aggregate accrued interest due on the Notes, divided by $0.40 (the "Conversion Price"). ( 2 )The reported securities in this row are held of record by IBF 1. Israel Biotech Fund GP Partners, L.P. ("IBF I GP"), a Cayman Islands Exempted Limited Partnership, is the general partner of IBF 1. I.B.F Management Ltd. ("IBF Management"), an Israeli private company, is the management company of IBF I GP. By virtue of such relationships, IBF 1 GP and IBF Management may be deemed to have shared voting and investment power with respect to the securities held of record by IBF 1. Each of IBF 1 GP and IBF Management disclaims beneficial ownership of the securities held by IBF 1, except to the extent of their pecuniary interest therein, if any. ( 3 )The reported securities in this row are held of record by IBF 2. Israel Biotech Fund GP Partners II, L.P. ("IBF II GP"), a Cayman Islands Exempted Limited Partnership, is the general partner of IBF 2. IBF Management is the management company of IBF 2 GP. By virtue of such relationships, IBF 2 GP and IBF Management may be deemed to have shared voting and investment power with respect to the securities held of record by IBF 2. Each of IBF 2 GP and IBF Management disclaims beneficial ownership of the securities held by IBF 2, except to the extent of their pecuniary interest therein, if any. ( 4 )On 11/17/2023, Issuer issued to IBF 1 and IBF II Amended and Restated Senior Secured Convertible Promissory Notes with a principal amount of $1,500,000 and $500,000, respectively (the "A&R Notes"), and, in connection therewith, warrants to purchase 5,625,000 shares of Common Stock and 1,875,000 shares of Common Stock, respectively, at an exercise price of $0.40 per share, subject to adjustments (the "A&R Warrants"). As more fully described in the Schedule 13D/A, on 2/7/2024, the A&R Notes were converted into 3,887,438 shares of Common Stock and 1,295,813 shares of Common Stock, respectively, which number of shares represents the aggregate principal amount plus aggregate accrued interest due on the Notes, divided by the Conversion Price. ( 5 )As more fully described in the Schedule 13D/A, (i) IBF I exercised an aggregate of 8,437,500 Warrants and A&R Warrants it holds (through a "cashless exercise") and, on 2/7/2024, the Issuer issued to IBF I a total of 5,729,919 shares of Common Stock in respect thereto (which reflects a total of 2,707,581 shares "withheld" by the Issuer in connection with the "cashless exercise" of such warrants to satisfy the aggregate exercise price of such warrants, based on the daily VWAP of the shares of Common Stock of $1.2465), and (ii) IBF II exercised an aggregate of 8,062,500 Warrants and A&R Warrants it holds (through a cashless exercise) and, on 2/7/2024, the Issuer issued to IBF II a total of 5,475,595 shares of Common Stock in respect thereto (which reflects a total of 2,586,905 shares "withheld" by the Issuer in connection with the "cashless exercise" of such warrants, based on the daily VWAP of the shares of Common Stock of $1.2465). ( 6 )The remaining derivative securities reported in this row reflect the rights of IBF I and IBF II to purchase senior convertible promissory notes on the same terms (including with respect to warrant coverage) as the Notes, as previously reported on Form 4 filed by the Reporting Persons on 11/21/2023.

Remarks: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the Reporting Persons may be deemed to be "directors by deputization" of the Issuer by virtue of their representatives on the Issuer's board of directors.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.